Anti-mens DR5 (Drozitumab) HRP

Expression Host : HEK-293 This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Drozitumab. Clone PRO95780 recognizes human death receptor 5 (DR5) . This product is for research use only. Drozitumab is a monoclonal antibody that specifically binds to human DR5. DR5 is expressed in a variety of solid tumors and hematologic malignancies, which are characteristically resistant to apoptosis. Drozitumab is a proapoptotic receptor agonists (PARA) that induces apoptosis in a variety of human cancer cell lines and xenograft models, both alone and in tandem with other antineoplastic agents.1 Apoptosis of cancer cells triggered by the activation of DR5, occurs without affecting most normal cell types. Anti-Human DR5 (Drozitumab) utilizes the same variable regions from the therapeutic antibody Drozitumab making it ideal for research projects.

DR5; CD262; KILLER; TRICK2; TRICKB; ZTNFR9; TRAILR2; TRICK2A; TRICK2B; TRAIL-R2; KILLER/DR5

Human

DR5 scFv

DR5

PRO95780

ELISA

Concentration : 0.5 mg/mlThis HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase)

This horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C. Do not freeze.

The suggested concentration for Drozitumab biosimilar antibody for staining cells in flow cytometry is <= 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.ELISA

Human IgG1lambda